ImmunityBio Sees Booster Role For Under-The-Tongue COVID-19 Vaccine
Novel Vaccine Focused On T-Cell Immunity
In search of a differentiated approach, candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
You may also be interested in...
US regulators indicate that authorizing booster shots is not a priority - but Pfizer still plans to seek an EUA in the fall.
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.